Report on the autologous transplant mainly conditioned with intravenous melphalan in 43 chinese children with advanced malignant solid tumours

Chen Jing,Dong Lu,Zhou Min,Gu Longjun,Tang Jingyan,Xue Huiliang,Pan Ci,Wang Yaoping

DOI: https://doi.org/10.3969/j.issn.1673-5323.2007.01.001

2007-01-01

Abstract:Objective To evaluate the safety and efficiency of conditioning regimen mainly with intravenous melphalan for children with advanced malignant solid tumours and explore the appropriate dosage of memlphalan for Chinese children. Methods Retrospective analysis for autologous transplant mainly with intravenous melphalan in 43 children with advanced malignant solid tumours was performed in our center. Carboplatin 350 mg/m2·d×2 d+VP16 300 mg/m2·d×2d and intravenous melphalan 140 mg/m2 were used for bone marrow transplant. Carboblatin 300 mg/m2·d×4d, VP16 160 mg/m2·d×4d and intravenous melphalan 210 mg/m2 were used for peripheral stem cell transplant. 180 mg/m2 melphalan was used for the patients when the hematological function couldn't recover within 30 days after chemotherapy or the number of nuclear cell in autograft was less than 3×108/kg. The side-effects were monitored and the speed of hematopoietic rehabilitation and the prognosis for these patients were evaluated. Results Mean age of this group was 7.6±4.2(1~17) years and mean body weight was 26.8±13.9 (9.5~52) kg. Totally 45 autologous transplant were finished among these 43 patients because 2 patients received 2 consecutive transplants including 8 with bone marrow transplant and 37 with peripheral precursor transplant. The dosage of melphaelan was 140 mg/m2 in 8 cases, 180 mg/m2 in 10 cases and 210 mg/m2 in rest of 27 cases. Diarrhea was the most common side effect which occurred in 26 cases (57%) after 2~3 days of melphalan administration accompanied abdominal pain, discomfort in precardiac region and oral mucositis lasting 3~7 days. All the patients with the mean time for absolute neutrophil over 0.5×109/L was 11.4±8.5 days and palate over 20×109/L was 21.4±9.5 except one who received melphalan 180 mg/m2 had poor recovery of the hematopoietic function after transplantation. There was no significant difference of hematologic recovery between patients received different dosage of melphalan. The mean duration for following up lasted for 16.1±14.2 months (2~65 months), 17 cases (39%) relapsed with mean period 14.2±9.68 (3~34) months post transplant, among them 12 was neuroblastoma. 26 children (61%) are still remaining disease free survival. No transplant related mortality could be found in our group up to now. Conclusion The conditioning regimen consisting of melphalan 180 mg/m2~210 mg/m2 and combination of carboplatin VP16 was safe and effective for the Chinese children with advanced malignant solid tumours. The common side effect in intravenous melphalan is mucositis. 210 mg/m2 of melphalan should be considered as the right dosage when the number of stem cells is enough and the potential of bone marrow recovery is good after sequence chemotherapy. The regimen for patients with advanced neuroblastoma should be further explored.